World Journal of Laparoscopic Surgery

Register      Login

VOLUME 7 , ISSUE 1 ( January-April, 2014 ) > List of Articles


Polycystic Ovarian Syndrome: Pathophysiology and Infertility

Bassim Alsadi

Citation Information : Alsadi B. Polycystic Ovarian Syndrome: Pathophysiology and Infertility. World J Lap Surg 2014; 7 (1):23-27.

DOI: 10.5005/jp-journals-10033-1212

Published Online: 01-12-2016

Copyright Statement:  Copyright © 2014; The Author(s).


Materials and methods

Extensive review of literature of articles published in English language was conducted using the following engines: Google, Yahoo, Medline, PubMed and Medscape.

How to cite this article

Alsadi B. Polycystic Ovarian Syndrome: Pathophysiology and Infertility. World J Lap Surg 2014;7(1):23-27.

PDF Share
  1. Amenorrhea associated with bilateral polycystic ovaries. Am J Obstet Gynecol 1935;29:181-191.
  2. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril 2004 Jan;81(1):19-24.
  3. Assessment and management of polycystic ovary syndrome: summary of an evidencebased guideline. Med J Aust 2011.
  4. Multifollicular ovaries: clinical and endocrine features and response to pulsatile gonadotropin releasing hormone. Lancet 1985;2:1375-1379.
  5. Prevalence of polycystic ovaries in women with anovulation and idiopathic hirsutism. BMJ 1986;293:355-359.
  6. Ultrasound assessment of the polycystic ovary: international consensus definition. Hum Rep Update 2003;9:505-514.
  7. The prevalence of polycyctic ovaries in healthy women. Acta Obstet Gynecol Scand 1999;78:137-141.
  8. Ultrasound for the evaluation of PCOS. in: Azziz R, Nestler J, Dewailly D, editors. Androgen excess disorder in women. Philadelphia: Lippincott-Raven Publishers 1997;269-278.
  9. A new ultrasound criterion for the diagnosis polycystic ovary syndrome: the ovarian stroma/total area ration. Fert Ster 2001;76:326-331.
  10. Insulinsensitising drugs (metformin, rosiglitazone, pioglitazone, D-chiro-inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility. Cochrane Database Syst Rev 2012.
  11. Transvaginal color doppler determination of the ovarian and uterine blood flow characteristics in polycystic ovary disease. Fert Sterl 1996;65:510-516.
  12. Does ovarian blood flow distinguish between ovulatory and anovulatory patient with polycystic ovary syndrome? AJ Obstet Gynecol 2003;189:1283-1286.
  13. Serum vacular endothelial growth factor concentration and ovarian stromal blood flow are increased in women with polycystic ovaries. Hum Reprod 1998;13:651-655.
  14. Current concepts in the polycystic ovary syndrome. Rev Med 2001;52:401-419.
  15. Profound peripheral insulin resistance, independent of obesity, in polycystic ovary syndrome. Diabetes 1989;38:1165-1174.
  16. Insulin resistence and polycystic ovary syndrome: mechanisms and implications for pathogenosis. Endocr Rev 1997;18:774-800.
  17. The involvement of inositolphosphoglican mediators in the modulation of steriodogenosis by insulin and insulin-like growth factor-1. Endocrinology 1993;132:1561-1568.
  18. Phosphatidylinositol 3-kinase-independent insulin action pathway (s) in the human ovary. J Clin Endocrinol Metab 2001;86:3115-3119.
  19. Lean women with polycystic ovary syndrome respond to insulin reducation with decrease in ovarian p450c17 alpha activity and serum androgens. Clin Endocrinol Metab 1997;82:4075-4079.
  20. The insulin-related ovarian regulatory system in health and desease. Endoc Rev 1999;20:535-582.
  21. Executive summary of the third report of the National cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults. J Am Med Assoc 2001 May 16;285(19):2486-2497.
  22. Anthropometric variables and meta- bolism in polycystic ovarian disease. Horm Metab Res 1989;21:391-397.
  23. Pathogenesis of polycystic ovary syndrome: what is the role of obesity? Metabolism 2004;53:358-376.
  24. Effect of weight loss and antiandrogenic therapy on sex-hormone blood levels and insulin resistance in obese patients with polycystic ovaries. Am J Obstet Gynecol 1985;154:139-144.
  25. Differences in clinical and endocrine features between obese and non-obase subjects with polycystic ovary syndrome: an analysis of 263 consecutive cases. Clin Endocrinol 1990;32:213-220.
  26. The cardiovascular risk of young women with polycystic ovary syndrome: an observational, analytical, prospective case-control study. J Clin Endocrinol Metab 2004;89:3696-3701.
  27. Troglitazone improves defects in insulin action, insulin secretion, ovarian steroidogenesis, and fibrinolysis in women with polycystic ovary syndrome. J Clin Endocrinol Metab 1997;82:2108-2116.
  28. Polycystic ovary syndrome is associated with obstructive sleep apnea and daytime sleepiness: role of insulin resistance. J Clin Endocrinol Metab 2001;86:517-520.
  29. A unique defect in the regulation of visceral fat cell lipolysis in the polycystic ovary syndrome as an early link to insulin resistence. Diabetes 2002;51:284-292.
  30. The perils of portliness: causes and consequences of visceral adiposity. Diabets 2000;49:883-888.
  31. New concepts in extracellular signaling for insulin action: the single gateway hypothesis. Recent Prog Horm Res 1997;52:359-385.
  32. Review of nonsurgical and surgical treatment and the role of insulin sensitizing agents in the management of infertile women with polycyctic ovary syndrome. Acta Obstet Gynecol Scand 2004;83:614-621.
  33. Obesity and female reproductive function. British medical bulletin 1997;53:341-358.
  34. Women with polycystic ovary syndrome gain regular menstrual cycles when ageing. Hum reprod 2000;15(1):24-28.
  35. Hyperfunction of the hypothalamic-pituitary axis in women with polycystic ovary disease: indirect evidence for partial gonadotropin desensitization. J Clin Edocrinol metab 1988;66:165-172.
  36. Pulsatile gonadotropinreleasing hormone stimulus is required to increase transcription of the gonadotropin subunit genes: evidence for differential regulation of transcription by pulse frequency in vivo. Endocrinology 1991;128:509-517.
  37. Polycystic ovarian sindrome: evidence that flutamide restores sensitivity of the gonadotropinreleasing hormone pulse generator to inhibition by estradiol and progesterone. J Clin Endocrinol Metab 2000;85:4047-4052.
  38. Clinical assessment of body hair growth in women. JC Endoc metab 1961;21:1440-1447.
  39. Hirsutism in polycystic ovary syndrome: current concepts. Clin obs Gynecol 1991;34:817-826.
  40. Differential androgen response to adrenocorticotropic hormone stimulation in polycystic ovarian sindrome: relationship with insulin secretion. Fertil Steril 1992;58:296-301.
  41. Polycystic ovary syndrome: the spectrum of the disorder in 1741 patients. Hum Repr 1995;10:2107-2111.
  42. The polycystic ovarian syndrome presenting as resistant acne successfully treated with cyproterone acetate. Med J Australia 1991;155:677-680.
  43. The polycystic ovary syndrome. Aust NZJ Obstet Gynecol 1989;29(4):403-416.
  44. Recurrent early miscarriage and polycystic ovaries. BMJ 1988;297:1027-1028.
  45. Influence of serum luteinising hormone concentration on ovulation, conception, and early pregnancy loss in polycystic ovary sindrome. BMJ 1988;297:1024-1026.
  46. The pathogenesis of infertility and early pregnancy loss in polycystic ovary syndrome. in: Arulkumaran S, editor. Clin obstet Gynaecol 2004;18(5):755-771.
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.